MOMichael H. Ossipov

Michael H. Ossipov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael H. Ossipov has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache

    by M.H. Ossipov, R.B. Raffa, Jr. Pergolizzi

    Migraine is a common, painful and highly disabling neurological condition that has plagued mankind for millennia, but its pathophysiology remained largely obscure until recently. The clinical success of triptans for treating migraine and the discovery that calcitonin gene-related peptide (CGRP) plays a prominent role in migraine led to increased research interest into this disease. An important improvement has been the development of monoclonal antibodies, including galcanezumab, that bind to CGRP or to its receptor, preventing its activation. Subsequent clinical trials have reported that galcanezumab is safe and well tolerated, and is effective in reducing the frequency of migraine attacks in patients with episodic or chronic migraine. At the same time, increased study of the pathophysiology of cluster headache, a relatively rare condition with excruciatingly painful headache attacks (i.e., "suicide headaches"), led to the discovery that, as in migraine, CGRP plays an important role in its pathology. Clinical trials suggest that galcanezumab is safe and effective for the prevention of episodic cluster headache, and it is under study for chronic cluster headache. Galcanezumab is approved for the prevention of migraine in the U.S., the European Union, Canada and Mexico, and was also approved for the treatment of episodic cluster headache in the U.S.


  • Open Access

    Discovery of “folded DNA” structures in human cells: Potential drug targets

    by Robert B. Raffa, Joseph V. Pergolizzi, Robert Taylor, Michael H. Ossipov, the NEMA Research Group

    What is known and objective The double‐helical conformation of human DNA (hDNA) is so axiomatic that it is called the “canonical” form. Recently, though, intrastrand folds (“I‐motifs” and “G‐quadruplexes”) have been identified in hDNA. These could be targets for novel drug discovery. Comment Any interruption of the canonical form of hDNA fundamentally impacts the normal progression of transduction and translation. In particular, the synthesis of receptors and cognate protein ligands would be affected, as well as their affinity for—and signal transduction of—pharmacotherapeutic agents. Recent studies have identified normally occurring, folded structures superimposed on the usual double‐helix motif of hDNA. What is new and conclusion The newly identified “folded DNA” structures (“I‐motifs” and “G‐quadruplexes”) could represent novel drug‐discovery targets, most likely for cancer.


  • Cortical and Subcortical Modulation of Pain

    by Milena De Felice, Michael H Ossipov

    Pain is more than merely nociception and response, but rather it encompasses emotional, behavioral and cognitive components that make up the pain experience. With the recent advances in imaging techniques, we now understand that nociceptive inputs can result in the activation of complex interactions among central sites, including cortical regions that are active in cognitive, emotional and reward functions. These sites can have a bimodal influence on the serotonergic and noradrenergic descending pain modulatory systems via communications among the periaqueductal gray, rostral ventromedial medulla and pontine noradrenergic nuclei, ultimately either facilitating or inhibiting further nociceptive inputs. Understanding these systems can help explain the emotional and cognitive influences on pain perception and placebo/nocebo effects, and can help guide development of better pain therapeutics.


  • Open Access

    The Perception and Endogenous Modulation of Pain

    by Michael H. Ossipov

    Pain is often perceived an unpleasant experience that includes sensory and emotional/motivational responses. Accordingly, pain serves as a powerful teaching signal enabling an organism to avoid injury, and is critical to survival. However, maladaptive pain, such as neuropathic or idiopathic pain, serves no survival function. Genomic studies of individuals with congenital insensitivity to pain or paroxysmal pain syndromes considerable increased our understanding of the function of peripheral nociceptors, and especially of the roles of voltage-gated sodium channels and of nerve growth factor (NGF)/TrkA receptors in nociceptive transduction and transmission. Brain imaging studies revealed a “pain matrix,” consisting of cortical and subcortical regions that respond to noxious inputs and can positively or negatively modulate pain through activation of descending pain modulatory systems. Projections from the periaqueductal grey (PAG) and the rostroventromedial medulla (RVM) to the trigeminal and spinal dorsal horns can inhibit or promote further nociceptive inputs. The “pain matrix” can explain such varied phenomena as stress-induced analgesia, placebo effect and the role of expectation on pain perception. Disruptions in these systems may account for the existence idiopathic pan states such as fibromyalgia. Increased understanding of pain modulatory systems will lead to development of more effective therapeutics for chronic pain.


  • Growth Factors and Neuropathic Pain

    by Michael H. Ossipov

    A treatment for neuropathic pain is an important unmet medical need because this pain often is refractory to many medical interventions. An important element in the development of neuropathic pain is a dysfunction in the activity of peripheral nerves. Because neurotrophic factors affect nerve development and maintenance, modulating the activity of these factors can alter neuronal pathophysiology and produce a disease-modifying effect. Blocking the activity of nerve growth factor or enhancing the activity of either glial-derived neurotrophic factor or artemin has shown potential for normalizing neuronal activity and attenuating signs of neuropathic pain in animal models and clinical studies. This article discusses the role of these factors in neuropathic pain and the implications for the development of novel therapeutics.


  • Contributors

    by A Vania Apkarian, Mark Baccei, Miroslav Backonja, Panos Barlas, Ralf Baron, Allan I Basbaum, Carlos Belmonte, David Lh Bennett, Charles B Berde, Karen J Berkley, et al.